Research Article Details
| Article ID: | A10393 |
| PMID: | 31357755 |
| Source: | Zhonghua Gan Zang Bing Za Zhi |
| Title: | [Machanism and intervention of nonalcoholic steatohepatitis-associated fibrosis]. |
| Abstract: | Main indication of nonalcoholic steatohepatitis (NASH) progression is hepatic fibrosis. The extent of fibrosis correlates negatively with long-term comorbidity and survival of NASH patients. Clinical screening for hepatic fibrosis extent higher than F2 is a main criterion for high risk NASH patients. Currently on-going phase III clinical trials for potential pharmacotherapeutics recruit NASH patients with F2-3, and whether tested pharmacotherapeutics block hepatic fibrosis is one of main end-points for assessment of clinical efficacy. Therefore, understanding molecular mechanisms and identifying potential targets are critical for intervention of NASH progression. |
| DOI: | 10.3760/cma.j.issn.1007-3418.2019.06.005 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S03 | Anti-fibrosis | fibrosis | Angiotensin Receptor Blocker (ARB); CCR2/CCR5 antagonist; Thyroid receptor β agonist; PEGylated human FGF21 analogue; Monoclonal antibody to lysyl oxidase-like 2 (LOXL2); Galectin-3 inhibitor; FGF19 variant | Losartan; Cenicriviroc; VK-2809; MGL-3196; Pegbelfermin; Simtuzumab; GR-MD-02; NGM282 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|